Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
نویسندگان
چکیده
Infection with voriconazole-resistant fungi may become problematic, because organisms with decreased susceptibility have been noted. Breakthrough fungal infections occurred in 13 of 139 patients who received voriconazole at our center during the period of September 1998 through September 2003. Zygomycetes were found in 6 patients, and Candida glabrata bloodstream infection occurred in 4 patients. Minimal inhibitory concentrations were > or =1 microg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis.
منابع مشابه
Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
Aspergillus ustus is an uncommon clinical species which is poorly susceptible to antifungals. We report two cases of A. ustus infections that occurred in allogeneic stem cell transplant recipients while they were receiving either voriconazole or caspofungin. Prolonged use of these new antifungal agents may increase the risk of the emergence of resistant organisms.
متن کاملDisseminated Fusariosis Following Cutaneous Injury From Contact With a Palm Tree
Opportunistic fungal infections are increasingly common in patients who undergo hematopoietic stem cell transplant (HSCT). Voriconazole is frequently used in allogeneic SCT recipients who receive immunosuppressant therapy for graft versus host disease to prevent invasive aspergillosis. Indications for voriconazole use include invasive aspergillosis, candidemia, Scedosporium apiospermum infectio...
متن کاملVoriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
BACKGROUND Recurrence of prior invasive fungal infection (relapse rate of 30-50%) limits the success of stem cell transplantation. Secondary prophylaxis could reduce disease burden and improve survival. DESIGN AND METHODS A prospective, open-label, multicenter trial was conducted evaluating voriconazole (4 mg/kg/12 h intravenously or 200 mg/12 h orally) as secondary antifungal prophylaxis in ...
متن کاملImmunotherapy for invasive fungal infections in transplant patients: back to the future?
In the past decade, we have witnessed striking advances in the diagnosis and therapy of invasive fungal infections in immunocompromised patients. Similar to the quantum leap in HIV medicine about 15 years ago, this progress resulted from the synergy of new diagnostic assays (galactomannan antigen, beta-glucan, (pan-)fungal polymerase chain reaction), with new and better antifungal drugs such as...
متن کاملAntifungal Therapy in Hematopoietic Stem Cell Transplant Recipients
Invasive fungal infections (IFI) represent a major hindrance to the success of hematopoietic stem cell transplantation (HSCT), contributing substantially to morbidity and infection-related mortality. During the most recent years several reports indicate an overall increase of IFI among hematologic patients, in particular, invasive aspergillosis, that may be explained, at least partially, by the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
دوره 39 5 شماره
صفحات -
تاریخ انتشار 2004